Ibaraki, Japan

Hideaki Sato

This inventor holds 3 USPTO granted patents and 2 EPO patents. Top assignees: Genedesign, Inc., Chiba University, National Institutes of Biomedical Innovation, Health and Nutrition. Active years: 2020-2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Hideaki Sato. Retrieved from https://idiyas.com/inventor/hideaki-sato-deacylri

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0


Average Co-Inventor Count = 3.6

ph-index = 1

Forward Citations = 1(Granted Patents)


Location History:

  • Osaka, JP (2020)
  • Ibaraki, JP (2022)

Company Filing History:


Years Active: 2020-2022

Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Innovations in Cancer Treatment: The Work of Hideaki Sato

Introduction

Hideaki Sato, an innovative inventor based in Ibaraki, Japan, has made significant contributions to the field of biomedical technology. With a total of three patents to his name, Sato has focused on advancing cancer treatment methodologies, showcasing his dedication to improving healthcare outcomes through scientific innovation.

Latest Patents

Sato's latest patents encompass a remarkable technique for treating cancer that utilizes structurally-reinforced S-TuD. This invention outlines a composition aimed at the prevention or treatment of tumors, which comprises an miRNA inhibitory complex that includes RNA or an analog thereof. The patent details a method for deploying this composition effectively. Central to this innovative approach is the miRNA inhibitory complex, which preferably contains at least one double-stranded structure along with an miRNA-binding sequence. Notably, two strands of the miRNA binding sequence are designed to attach individually to strands at one end of the double-stranded structure. Furthermore, the invention includes a sophisticated delivery system for administering the miRNA inhibitory complex.

Additionally, Sato has developed non-aggregating immunostimulatory oligonucleotides, further enhancing the toolkit for nucleic acid medicines. This patent introduces a delivery agent containing a nucleic acid with a phosphorothioated nucleotide, along with an oligonucleotide featuring a bioactive core. This innovative immunostimulator falls under types A/D, B/K, or C immunostimulatory oligonucleotides, showcasing Sato’s commitment to advancing therapeutic methodologies.

Career Highlights

Throughout his career, Hideaki Sato has been associated with reputable organizations such as Genedesign, Inc. and the National Institutes of Biomedical Innovation, Health and Nutrition. His roles in these institutions have positioned him at the forefront of research and development in biomedical technology, contributing to his success as an inventor.

Collaborations

Sato has collaborated with prominent figures in his field, including Hideo Iba and Takeshi Haraguchi. These partnerships highlight the collaborative spirit of innovation and the importance of teamwork in achieving groundbreaking advancements in scientific research.

Conclusion

Hideaki Sato continues to be a pivotal figure in the realm of cancer treatment innovations. Through his patents and career contributions, he exemplifies the essence of invention and the impact of dedicated research on public health. His work sets a benchmark for future inventors aspiring to make a difference in the biomedical landscape.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…